Worldwide Clinical Trials Expert to Present on Patient Engagement at DIA 2017

Barbara Zupancic, MBA, MSc, to discuss best practices for developing and implementing a patient-centered approach to effectively engage subjects in varying stages of Alzheimer’s Disease.

MORRISVILLE, N.C.--()--Barbara Zupancic, MBA, MSc, Director, Global Patient Recruitment and Retention at Worldwide Clinical Trials (www.worldwide.com), will present at one of the life sciences industry’s key events – the annual meeting of the DIA (Drug Information Association), being held June 18-21, 2017 in Chicago, Illinois.

With patient engagement being a hot topic across the industry with potential touchpoints throughout the life cycle of a product or portfolio, Zupancic will speak about “Driving Engagement in All Phases of Alzheimer’s Disease: Creating Lasting Engagement and Achieving Trial Success” during a panel session. This 90-minute collaborative session will be chaired by Jane Myles, Head of Operational Intelligence and Innovation, Product Development Global Operations at Genentech, and will take place Monday, June 19 at 11 a.m. CT.

“I’m honored to be presenting at DIA 2017,” commented Zupancic. “This panel discussion presents a great opportunity for the leaders in our field to discuss recruiting patients in different stages of cognitive impairment which requires targeted outreach, engagement and retention strategies. I will be discussing best practices for developing and implementing a patient-centered approach that is focused on using the right channels and messaging for faster recruitment and lasting engagement, including how we demonstrate value and measure outcome and impact.”

In addition to Zupancic’s presentation, experts from the Worldwide Clinical Trials team will be on-hand at the company’s booth (#1316) to discuss the individual drug development challenges of attendees, as well as their needs across a range of therapeutic areas, including central nervous system disorders, cardiovascular disease, immune-mediated inflammatory disorders and rare diseases. For more information about Worldwide at DIA 2017, visit www.worldwide.com/DIA.

The DIA annual meeting, now in its 53rd year, is the largest, longest-running event in the life sciences industry and attracts more than 7,000 global health care professionals in the pharmaceutical, biotechnology and medical device communities from more than 51 countries.

Connect with Worldwide Clinical Trials:

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world’s leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases. For more information, visit worldwide.com.

Contacts

Worldwide Clinical Trials
Matt Harrington, 610-964-2000 / 610-724-7301.
Matt.Harrington@worldwide.com

Release Summary

Barbara Zupancic, MBA, MSc, to discuss best practices for developing and implementing a patient-centered approach to effectively engage subjects in varying stages of Alzheimer’s Disease at DIA 2017.

Contacts

Worldwide Clinical Trials
Matt Harrington, 610-964-2000 / 610-724-7301.
Matt.Harrington@worldwide.com